share_log

Catheter Precision, Inc. (NYSE-American: VTAK) Announces New Chief Commercial Officer

Catheter Precision, Inc. (NYSE-American: VTAK) Announces New Chief Commercial Officer

Catheter Precision, Inc.(紐約證券交易所美國股票代碼:VTAK)宣佈新任首席商務官
Accesswire ·  05/01 20:00

FORT MILL, SC / ACCESSWIRE / May 1, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), is pleased to announce and welcome Marie-Claude Jacques as Chief Commercial Officer. Marie-Claude will be responsible for the commercialization team including sales and marketing to develop new business opportunities and improve the customer experience.

南卡羅來納州米爾堡/ACCESSWIRE/2024 年 5 月 1 日/Catheter Precision, Inc.(紐約證券交易所美國股票代碼:VTAK)很高興地宣佈並歡迎 Marie-Claude Jacques 擔任首席商務官。Marie-Claude將負責商業化團隊,包括銷售和營銷,以開發新的商機並改善客戶體驗。

"As a growing medical device company, we need a sales leader that can facilitate a growth strategy to move us forward," says David Jenkins, CEO of Catheter Precision. "We are excited to welcome Marie-Claude on board to enable and empower the success of our sales team for the future."

Catheter Precision首席執行官戴維·詹金斯表示:“作爲一家成長中的醫療器械公司,我們需要一位能夠促進增長戰略以推動我們向前發展的銷售領導者。”“我們很高興歡迎Marie-Claude加入,爲我們的銷售團隊未來取得成功提供支持和支持。”

Before joining Catheter Precision Inc, Mrs. Jacques worked as Area Vice President, Commercialization & Strategy at Boston Scientific Corporation, a Fortune 500 manufacturer of medical devices used in cardiac rhythm management, peripheral interventions, endoscopy, neuromodulation, and urology/pelvic health. Marie-Claude's role at Boston Scientific followed a very successful 15 years in sales leadership at Baylis Medical where she was responsible for building and scaling the US business. The strategic plans that Marie-Claude put in place at Baylis Medical allowed the company to have high double-digit sales growth for several consecutive years. This, combined with her work in market development, were key to becoming the standard-of-care in left heart access in the US. The company's success led to the acquisition by Boston Scientific for $1.75B USD.

在加入Catheter Precision Inc之前,Jacques女士曾在波士頓科學公司擔任商業化與戰略區域副總裁。波士頓科學公司是一家財富500強制造商,生產用於心律管理、外周干預、內窺鏡檢查、神經調節和泌尿科/骨盆健康的醫療器械。瑪麗-克勞德在波士頓科學公司任職之前,她曾在貝利斯醫療公司成功擔任銷售領導職務15年,負責建立和擴展美國業務。瑪麗·克勞德在Baylis Medical制定的戰略計劃使該公司連續幾年實現兩位數的高銷售增長。再加上她在市場開發方面的工作,是成爲美國左心通路醫療標準的關鍵。該公司的成功促使波士頓科學以17.5億美元的價格收購。

"I am passionate about building high performance teams," says Mrs. Jacques. "My sweet spot is fast-paced, high-growth, small to mid-size organizations entering new markets. I have proven success in scaling organizations to optimize results, most recently with Baylis Medical Company. I am honored to be joining Catheter Precision, Inc. and have no doubt in my mind that the organization has a bright future."

雅克夫人說:“我熱衷於建立高績效團隊。”“我的最佳選擇是快節奏、高增長、中小型組織進入新市場。事實證明,我在擴大組織規模以優化結果方面取得了成功,最近在Baylis Medical Company工作過。我很榮幸加入Catheter Precision, Inc.,我毫不懷疑該組織的前途光明。”

David Jenkins continued, "Over the last two months we have onboarded a great group of salespeople, all of whom are excited to see Marie-Claude coming in as the leader of our revenue team. Her initial conversations with members of the team confirm my confidence in the product pipeline development. I am convinced that Marie-Claude Jacques is an excellent addition to our company."

大衛·詹金斯繼續說:“在過去的兩個月中,我們招募了一大批銷售人員,他們都很高興看到Marie-Claude成爲我們的收入團隊的負責人。她與團隊成員的初步對話證實了我對產品管道開發的信心。我堅信,瑪麗·克勞德·雅克是我們公司的絕佳補充。”

As an inducement to Mrs. Jacques' employment, she received an award of options to purchase 250,000 shares of Company common stock. The options were granted pursuant to Section 711(a) of the NYSE American listed company manual, which provides that qualifying inducement awards may be made without obtaining shareholder approval. The options have an exercise price of $0.5321 per share, vest annually over five years and have a term of 10 years.

作爲鼓勵雅克夫人就業的誘因,她獲得了購買公司25萬股普通股的期權獎勵。這些期權是根據紐約證券交易所美國上市公司手冊第711(a)條授予的,該手冊規定,未經股東批准即可發放合格的激勵獎勵。這些期權的行使價爲每股0.5321美元,在五年內每年歸屬,期限爲10年。

About Catheter Precision

關於導管精度

Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products. Reincorporated as Ra Medical Systems, Inc. in Delaware in 2018, the Company changed its name to Catheter Precision, Inc. on August 17, 2023.

Catheter Precision是一家總部位於美國的創新醫療器械公司,爲市場帶來了改善心律失常治療的新解決方案。它專注於通過與醫生合作並不斷改進其產品,爲電生理學手術開發開創性的技術。該公司於2018年在特拉華州重組爲Ra Medical Systems, Inc.,並於2023年8月17日更名爲Catheter Precision, Inc.

Cautionary Note Regarding Forward-Looking Statements
This communication contains forward-looking statements. Forward-looking statements can be identified by words such as "believe," "anticipate," "may," "might," "can," "could," "continue," "depends," "expect," "expand," "forecast," "intend," "predict," "plan," "rely," "should," "will," "may," "seek," or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include, but are not limited to, the following: statements regarding the Company's potential future performance. The Company's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption "Risk Factors" in the Company's Form 10-K filed with the SEC and available at www.sec.gov. These risks and uncertainties include, but aren't limited to, that we do not have sufficient liquidity to fund our operations through May 2024 unless we are able to obtain additional financing or enter into a strategic transaction that would provide additional liquidity, we will not be able to reach profitability unless we are able to achieve our product expansion and growth goals, our research and development and commercialization efforts may depend on entering into agreements with corporate collaborators, we have entered into joint marketing agreements with respect to our products, and may enter into additional joint marketing agreements, that will reduce our revenues from product sales, royalty agreements with respect to our LockeT device will reduce any future profits from this product, if we experience significant disruptions in our information technology systems, our business may be adversely affected, litigation and other legal proceedings may adversely affect our business, if we make acquisitions or divestitures, we could encounter difficulties that harm our business, failure to attract and retain sufficient qualified personnel could also impede our growth, failure to maintain effective internal controls could cause our investors to lose confidence in us and adversely affect the market price of our common stock, we have determined that our internal controls and disclosure controls were not effective as of December 31, 2023, and as a result, without effective remediation of the material weaknesses that we have identified, we may not be able to accurately report our financial results or prevent fraud, our revenues may depend on our customers' receipt of adequate reimbursement from private insurers and government sponsored healthcare programs, we may be unable to compete successfully with companies in our highly competitive industry, many of whom have substantially greater resources than we do, our future operating results depend upon our ability to obtain components in sufficient quantities on commercially reasonable terms or according to schedules, prices, quality and volumes that are acceptable to us, and suppliers may fail to deliver components, or we may be unable to manage these components effectively or obtain these components on such terms, if hospitals, physicians and patients do not accept our current and future products or if the market for indications for which any product candidate is approved is smaller than expected, we may be unable to generate significant revenue, if any, our medical device operations are subject to pervasive and continuing FDA regulatory requirements, our products may be subject to additional recalls, revocations or suspensions after receiving FDA or foreign approval or clearance, which could divert managerial and financial resources, harm our reputation, and adversely affect our business, changes in trade policies among the U.S. and other countries, in particular the imposition of new or higher tariffs, could place pressure on our average selling prices as our customers seek to offset the impact of increased tariffs on their own products, increased tariffs or the imposition of other barriers to international trade could have a material adverse effect on our revenues and operating results. The risks and uncertainties described above may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty, or other pandemics, supply chain disruptions from the Ukraine war or Israeli-Hamas conflict and otherwise, and ongoing volatility in the stock markets and the U.S. economy in general.

關於前瞻性陳述的警示說明
本通訊包含前瞻性陳述。前瞻性陳述可以通過諸如 “相信”、“預測”、“可能”、“可能”、“可以”、“繼續”、“取決於”、“期望”、“擴展”、“預測”、“打算”、“預測”、“計劃”、“依靠”、“應該”、“可能”、“尋求” 等詞語來識別,或者這些術語和其他類似表述的否定詞,儘管並非所有前瞻性陳述都包含這些詞語。這些前瞻性陳述受1995年《私人證券訴訟改革法》的安全港條款的約束。本新聞稿中包含的前瞻性陳述包括但不限於以下內容:有關公司未來潛在業績的聲明。公司對這些問題的期望和信念可能無法實現。由於不確定性、風險和情況變化,實際結果和業績可能與這些前瞻性陳述所設想的結果和業績存在重大差異,包括但不限於公司向美國證券交易委員會提交的10-K表中 “風險因素” 標題下包含的風險和不確定性,可在www.sec.gov上查閱。這些風險和不確定性包括但不限於,除非我們能夠獲得額外的融資或達成提供額外流動性的戰略交易,否則我們沒有足夠的流動性來爲2024年5月的運營提供資金;除非我們能夠實現產品擴張和增長目標,否則我們將無法實現盈利;我們的研發和商業化工作可能取決於與企業合作者的協議;我們已經與之簽訂了聯合營銷協議關於我們的產品,並可能簽訂額外的聯合營銷協議,這將減少我們的產品銷售收入,與我們的Locket設備相關的特許權使用費協議將減少該產品的任何未來利潤,如果我們的信息技術系統出現重大中斷,我們的業務可能會受到不利影響,訴訟和其他法律訴訟可能會對我們的業務產生不利影響,如果我們進行收購或剝離,我們可能會遇到損害我們業務的困難,無法吸引和留住我們的業務足夠的合格的人員也可能阻礙我們的增長,未能維持有效的內部控制可能導致我們的投資者對我們失去信心,並對普通股的市場價格產生不利影響,我們已經確定我們的內部控制和披露控制措施自2023年12月31日起無效,因此,如果不有效糾正我們已發現的重大弱點,我們可能無法準確報告財務業績或防止欺詐,我們的收入可能取決於客戶的收入足夠的私人保險公司和政府贊助的醫療保健計劃的報銷,我們可能無法與競爭激烈的行業中的公司成功競爭,其中許多公司的資源比我們多得多,我們未來的經營業績取決於我們能否以商業上合理的條件或根據我們可接受的時間表、價格、質量和數量獲得足夠數量的組件,供應商可能無法交付組件,或者我們可能無法有效地管理這些組件或獲得這些組件這些條款下的組成部分,如果醫院、醫生和患者不接受我們當前和未來的產品,或者任何候選產品獲得批准的適應症市場小於預期,我們可能無法創造可觀的收入,如果有的話,我們的醫療器械業務受美國食品和藥物管理局普遍持續的監管要求的約束,我們的產品在獲得美國食品藥品管理局或外國批准或許可後可能會被進一步召回、撤銷或暫停,這可能會轉移和管理層的注意力財政資源,傷害我們聲譽,並對我們的業務產生不利影響,美國和其他國家之間貿易政策的變化,特別是徵收新的或更高的關稅,可能會給我們的平均銷售價格帶來壓力,因爲我們的客戶試圖抵消提高關稅、提高關稅或實施其他國際貿易壁壘的影響,可能會對我們的收入和經營業績產生重大不利影響。造成重大經濟不確定性的 COVID-19 疫情或其他流行病、烏克蘭戰爭或以色列-哈馬斯衝突等造成的供應鏈中斷,以及股市和整個美國經濟的持續波動,可能會加劇上述風險和不確定性。

The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

本通訊中包含的前瞻性陳述僅自本文發佈之日起作出。除非法律要求,否則公司不承擔任何義務,也不打算更新這些前瞻性陳述。

CONTACTS:
At the Company
David Jenkins
973-691-2000
IR@catheterprecision.com

聯繫人:
在公司
大衛詹金斯
973-691-2000
IR@catheterprecision.com

# # #

# #

SOURCE: Catheter Precision, Inc

來源:Catheter Precision, Inc


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論